ARE YOU ONE OF THEM?
*Presidential Proclamation 958, 2005 mandates Civil Society to help Government in eradicating Lifestyle Diseases. Of the 90%, 40.5% are sick with Cancer and Heart Diseases. The Department of Health is now working to promote programs to boost the Immune System, our best weapon against any disease!
DO YOU KNOW THAT COWS AND CHICKENS DON'T HAVE HEART ATTACKS AND CANCER?
Not because humans eat them before they get sick, but generally speaking they are spared from lifestyle diseases. In the following articles, you will discover that
Transfer Factor
could be the key factor to transfer all the immunity codes of
cows and chickens, who are exposed to all the pathogens of the earth,
to humans, thereby educating our immune system to prevent disease!
(Note: Transfer Factor is Not a Drug Nor a Cure for Diseases;
Transfer Factor will make your Immune System a Genius To Become
The Ultimate Killing Machines vs. Pathogens e.g. Viruses, Bacteria, Fungal
Parasites, Toxins, Cancer Cells and Foreign Bodies)
Click Here to Buy Transfer Factor On-Line
--------------------
TOP NEWS!!!! PLEASE SEE ITEM#4 BELOW
A FAST RECOVERY
OF A 55 YR OLD MAN FROM STROKE
IN JUST 2 DAYS WAS DISCHARGED
FROM THE HOSPITAL
PLEASE SEE ITEM#7 BELOW
AN AMAZING RECOVERY
OF A 43 YR OLD WOMAN FROM BREAST CANCER
IN JUST 3 MONTHS WITH NO
CHEMOTHERAPY
and
UNBELIEVABLE RECOVERY OF A
DYING 82 YR OLD MAN FROM
STAGE 4 PROSTATE CANCER IN
11 DAYS WALKED HOME
PLEASE SEE ITEM#11 BELOW IN 3 WEEKS, A HIGHLY CONTAGIOUS
HEPATITIS B WAS REVERTED TO
NON-INFECTIOUS STATE WHICH IS UNUSUAL.
[Please click on the above illustration for full view] (Author's Note: Below is an excerpt from Chapter 1 of my upcoming book)
UNDERSTANDING TRANSFER FACTOR IN LAYMAN'S TERMS by Ramon L. Mendoza
1. TRANSFER FACTOR DEFINED
Transfer Factors are one of nature’s most elegant form of immune communication. It awakens our sleeping immune surveillance cells to do its job properly.
"Transfer Factor is a miraculous discovery that was first made in 1949 - a tiny molecule in white blood cells, a communication molecule that helps alert immune system cells to what they ought to be doing", says David Lisonbee, CEO & Founder of 4Life Research LLC, Sandy Utah USA.
In medical parlance, according to Kirkpatrick, et. al, "Transfer Factors are peptides consisting of 44 amino acids. Transfer Factor molecules are smaller than antibodies and just one third the size of a virus and have molecular weights of less than 10,000 daltons (between 3,500 to 5,000 daltons). Transfer Factor (TF) (produced by 4Life Research, USA) is a hypoallergenic product, free of casein, lactoglobulins and other large proteins, but it does contain intact cytokine fractions identical to leukocytic cytokines. Academician A.A. Vorobiev of the Russian Academy of Medical Sciences points out that unlike other immunomodulators Transfer Factor has a wide spectrum of activity, is safe, is administered orally, has no contraindications or side effects, and is effective both in adults and children." Transfer Factor is not a vitamin, mineral, herb, antioxidant nor a drug. Transfer Factor is the IQ of the immune system. Transfer Factor is pioneering in Transferceutical Technology. The other supplements belong to the Neutraceutical Technology.
Transfer Factor is an information molecule that educates, enhances and balances the immune system. First, it educates or teaches the immune system cells to recognize diseases in the body and send these soldiers to attack and kill invaders such as bacterial, viral,
Vitamins, minerals, herbs and antioxidants are the building blocks of the immune system while Transfer Factor is the immune intelligence of the immune system.
You may watch the video link below to learn about the effects of Transfer Factor in preventing
and addressing Chronic Diseases e.g. Chronic Heart Diseases , Cardiovascular Diseases, Stroke and Hypertension. Visit http://mdprolife.multiply.com/video/item/2
2. DISCOVERY OF TRANSFER FACTOR
Transfer Factor was discovered in 1949 by Dr. Sherwood Lawrence, USA, while doing an experiment. He asked one question that no other doctor asked during his time: Can immunity be transferred from a donor to a recipient without having gone through the disease? So he went to his laboratory and did a series of tests. He extracted blood specimen from donors who have developed immunity on tuberculosis. He extracted the T-Cells from the white blood cells of these donors and injected it to his assistant who never had tuberculosis. In two days, a tuberculin test revealed that his assistant was sensitized to TB, just using the blood extracts. Dr. Lawrence was very glad at this phenomenal result. History was made confirming his theory that immunity is therefore transferable from one specie to another and vice-versa. He studied the blood samples in the laboratory and discovered that these strange molecules attached to the T-Cells were responsible for transferring the immunity, so he called them Transfer Factors. So the name Transfer Factor was born in 1949. This revolutionized medicine instantly. However, this was a time when science came in and told Dr. Lawrence to stop the regimen until he finds a safer and more suitable source of Transfer Factors other than the human blood.
In 1950, antibiotics became the golden child of medicine. Antibiotics’ popularity overshadowed Transfer Factor, which was eventually shelved.
In 1960, steroid became the golden child of medicine.
In the 70’s and 80’s, the urgent call for Transfer Factor was revived due to the overwhelming side effects and limiting power of drugs. Antibiotics are powerless when bacteria grow wiser. It has no effect on viruses. Steroids, on the other hand, made people bloated. Women grew hairs on their faces, and inflammation worsened causing more harm than good. At this time, 4Life Research was in the forefront and hundreds of scientists were challenged to find Transfer Factor in other sources. US$42 Million was spent on research. Finally, Transfer Factor was found, of all places, in the woman’s milk. Transfer Factor molecules where found in the milk called colostrum (available only during the first three days of milk upon birth).
Before this discovery, an interesting fact was recorded: In the early years, scientists and researchers observed that the milkmaids seldom got sick. Even during an epidemic, they were spared from fatal diseases. While thousands died, they remained healthy as ever. Milkmaids did not die of infectious diseases, and normally they die of old age. Their remarkable health led to the conclusion that milking cows may have something to do with it. The question arose: Can human beings get immunity from cows milk?
In several instances, when the young cows were separated at birth from their mothers, they die after six months.
Babies, too, that were not breast-fed during the first three days of birth became sickly and experienced more allergies, asthma and diarrhea attacks. These observations led to the discovery of Transfer Factor molecules in the first three days of milk called “Colostrum”. In cows, its found within the first five days or first 9 gallons of milk. The chicken egg yolk also contained similar Transfer Factor molecules. After testing these molecules they were found to be similar in structure and that they are non-species specific, meaning they can be transferred from humans to animals and vice-versa. They carry immunity codes or templates of antibodies transferred from mother to baby, which helps the young offspring survive the first six months of life.
3. AVERAGE LIFE SPAN
In spite of the medical advancement of the current generation defined by high-technology and modern inventions, still a growing number of diseases has successfully invaded the human body. Hospitals cannot deny its fast rising population of sick people and nothing seem to avert the growing menace of mortality rate. Even drugs and surgery has become top causes of mortality in hospitals. Instead of becoming healthier, people are getting sicker.
So to avert the growing menace of pharmaceutical limitations, the rise of neutraceuticals in the form of vitamins, herbs and antioxidants from 1970's to 1990's has improved the effects of medication. Then came in 1998 Transfer Factors, the transferceutical technology pioneering at the forefront of medicine. These combination has clearly improved average life span globally. Record shows that the average life span in the early 20th century is 30 to 45 years old versus the current global recent average of 65.82* in the year 2007.
*According to Wikipedia's website, World Average Ave. Life Span in 2007 is 65.82 Overall (63.89 Male, 67.84 Female).
The Freedictionary.com says "Life expectancy is the average number of years a human has before death, conventionally calculated from the time of birth, but also can be calculated from any specified age.
One of the biggest jumps in life expectancy coincided with the introduction of sewers, which greatly reduced the spread of disease. In the last few centuries a strong statistical effect was caused by the near elimination of infant mortality in the Western world and elsewhere.
Average life expectancy before the health transition of the modern era is thought to have varied between about 20 years and 35 years. It is important to note that most people who quote pre-modern life expectancies do so while calculating infant mortality into the mix. Also, the life expectancy for women was lower throughout history than it was for men; because, until modern medicine, one in four women died in childbirth. If you survived childhood you could expect to live into your old age in any time throughout history. It has been suggested that life expectancy fell with the introduction of plant and animal domestication because of:
- higher infection rates caused by the increase in human settlement size and density,
- poorer nutrition due to low dietary variety.
Life expectancy recovered somewhat, but it is only in recent centuries that it has dramatically increased. These changes are the result of a combination of factors including nutrition and public health, and medicine only marginally. The most important single factor in the increase is the reduction of death in infancy.
The greatest improvements have been in the richest parts of the world. Life expectancy increased dramatically in the 20th century. Life expectancy at birth in the United States in 1900 was 47 years. Life expectancy in India at mid-century was around 32, by 2000 it had risen to 64 years. According to the 2006 WHO Report, due to HIV/AIDS and other health related issues today's life expectancy in poorer nations is almost half that of the industrialized, richer nations."
(Source: http://encyclopedia.thefreedictionary.com/Average+life+span)
Transfer Factor could be the missing link to the real "fountain of youth". It has the ability to balance the body's immune system and correct immune abnormalities specially within the arterial walls. If your arteries are healthy and young, then you will look younger than your actual age. Then the ageing process can therefore be drastically slowed down just by rejuvenating and de-clogging your arteries.
To prove that Transfer Factor truly works on my arteries, I took Transfer Factor Tri-Factor Plus Advance Formula for straight 1 year maintenance of just 1 or 2 capsules a day . Then I took a DPA (Digital Pulse Analyzer) Analysis* to test my pulse rate and my biological arterial age and in just 3 minutes I got the following result as shown in the chart below: My Biological Arterial Age is now 35 versus my Actual Age of 48. I am therefore 13 years younger because of TF!
*Ref: http://www.shopmash.com/mash_dpa_info.htm
Again, the immune system is the most powerful weapon we have against any disease. If this is true, then why do people lose the battle against cancer, diabetes, heart disease and other fatal diseases? Why do people still get sick?
Answer: It is the lack of information.
Yes, this information is loaded in Transfer Factors over a span of centuries from generations to generation, from mother to baby. No wonder why instant milk formula is not enough. Mother's milk, specifically the colostrum is filled with transfer factors which provide the information codes needed by the babies to survive.
Answer: It is the lack of information.
Yes, this information is loaded in Transfer Factors over a span of centuries from generations to generation, from mother to baby. No wonder why instant milk formula is not enough. Mother's milk, specifically the colostrum is filled with transfer factors which provide the information codes needed by the babies to survive.
Who do you think is more obedient to the laws of nature when it comes to breast-feeding, the cow or the human being? Cows don't know how to mix instant formula milk , so its forced to breast-feed. We, humans do know how to mix. This is precisely the reason why Transfer Factors are no longer transferred to the human race in most families.
Lets face it, Mother Nature has programmed mothers to download gigabytes of immunity information codes to equip babies in the first months of life.
The cows and the chickens loiter everywhere and eat dirt to help them digest their food easily, so they are exposed to all kinds of diseases, but nature has endowed them with a heroic immune system enabling them to develop immunity faster than most animals. They develop antibodies and leave templates of these information called Transfer Factors which are passed on to the colostrum for cows and chicken egg yolk. 4Life Research extract these molecules and put them into capsules for oral intake. 4Life has patented this extraction process for the next 15 years.
This concludes the discovery of Dr. Sherwood Lawrence that immunity can thus be transferred from a donor to a recipient without having gone through the disease.
Transfer Factor enhances the immune system by boosting it beyond its original state up to 437% increase in killing rate or immune activation. With this outstanding ability, the immune system can now destroy 97% of cancer cells.
4. STROKE , CARDIOVASCULAR DISEASE , AUTOIMMUNE DISEASE & CHRONIC INFLAMMATION DISCUSSED
A case in point, chronic inflammation has been discovered in 2004 as the culprit for causing many of the top killer diseases such as heart disease, Alzheimer’s disease, diabetes and cancer. This was quoted by Time Magazine as featured in Feb 23, 2004 that : Chronic Inflammation is the engine that drives many of the most feared illnesses of middle and old age.
There are two main reasons for CHRONIC INFLAMMATION according to Dr. R. Bennett. First, invasion of microbes, bacteria, viruses or fungi. Second, auto-immunity. Auto-immunity means automatically the good cells fight other good cells by mistake for lack of information. This leads to immune erratic behavior leading to auto-immune disorders such as asthma, Graves' disease, severe atopic dermatitis (a.k.a. skin asthma), allergic rhinitis, psoriasis, allergies, lupus, diabetes, goutic arthritis, rheumatoid arthritis, Scleroderma, etc. This type of disease is also known as Ediopathic disease, coming from “ediopathy” or no known cause. So till today it has no known medication as well.
Logically, Transfer Factor is the answer to this problem. Transfer Factor is the information molecule that will educate the erratic immune cells to stop misfiring. So auto-immunity problems are controlled or balanced. However, one must take Transfer Factor as prophylaxis or as maintenance e.g. 2 capsules a day of Transfer Factor Tri-Factor Formula.
Local testimony on Atopic Dermatitis (a.k.a Skin Asthma or Atopic Eczema): A 21-year old woman who suffered from severe atopic dermatitis, a chronic infammation of the skin, also called atopic eczema, was told by her array of doctors from various hospitals that there is really no cure for it. However, her dad heard my interview on Transfer Factor over DialM Channel 4, and immediately went to see me last Oct 18, 2008. She started taking Transfer Factor Tri-FactorFormula : 2 capsules 2 x a day before each meal. In just 21 days she recovered. Now she's taking TF as maintenance supplement. Truly it was life changing as she's back to work. On top of that, as bonus she became a commercial model and an actress as her skin became so beautiful.
Do you know that Cardiovascular Disease is also due to Chronic Inflammation?
This is proven in 60 countries around the world where Transfer Factor is widely used. You may visit and try watching Dr. William L. Hennen's TF Cardio video on http://mdprolife.multiply.com/ to watch a video on how the heart can develop Cardiovascular Disease and how you can avoid it. According to him, Transfer Factor can help balance the immune system by guiding the T-Suppressor cells to convert IgE antibodies (Immunoglobulin E) production to IgG Antibodies, thus reversing the inflammatory procedure. This video talks about the invasion of bacteria inside the walls of the coronary artery which causes inflammation and can lead to atherosclerosis. This plaque formation inside the arterial walls start with bacterial infection attracting the macrophage (immune system cells in-charge of wiping away the debris left by infections) to accumulate and surround the bacteria, which oxidizes the HDL, High-Density Lipoprotein (good cholesterol), into LDL, Low-Density Lipoprotein (bad cholesterol), resulting into plaque accumulation or atherosclerosis. At this point, high blood occurs which if untreated may lead to bigger cardiovascular problems or even bypass surgery. However, with Transfer Factor, this can be reversed. The immune system cells will now have the ability to recognize the invading bacteria and launches an attack to kill the culprit bacteria and effectively destroying it therefore dissolving the plaque formation and commands the suppressor cells to balance it by flattening it back to its original state. This is a practical way to avoid surgery and angioplasty. Local Testimony on Stroke: Angel, 55 Year old man from Zamboanga del Sur, suffered stroke on June 19, 2010. He was half-body paralyzed and could not talk. He was confined in a hospital in Cebu City and immediately a friend by the name of Jun E. went to visit him and gave him TF Riovida (30ml 2 x a day) and TF Tri-Factor (2capsules 2 x a day). After 2 days, he stood up, talked like a normal person so he was discharged on the 3rd day June 22. Truly the product worked so fast.
"Cholesterol can’t dissolve in the blood. It has to be transported to and from the cells by carriers called lipoproteins. Low-density lipoprotein, or LDL, is known as “bad” cholesterol. High-density lipoprotein, or HDL, is known as “good” cholesterol. These two types of lipids, along with triglycerides and Lp(a) cholesterol, make up your total cholesterol count, which can be determined through a blood test. " - http://www.americanheart.org/presenter.jhtml?identifier=180
Transfer Factor supplementation is the safest, most effective and most economical way of cleansing and de-clogging the arterial walls of any microorganism or debris without surgery.
Dr. William J. Hennen has over 13 years of experience as an academic researcher/professor in drug design and development, with a Ph.D. in Bio-Organic Chemistry from Utah State University and he has written several books on Transfer Factor, where I got most of my knowledge.
Transfer Factor is the First Dietary Supplement Approved for use in Hospitals in Russia signed by the Ministry of Health and Social Development of Russia in 2004, which was a directive to all government hospitals in Russia to use Transfer Factor for all cancer and leukemic patients and for other infectious diseases e.g. HIV, Hepa-B, Hepa-C, etc.
5. CANCER CELLS
In the case of cancer, Transfer Factor (TF) is a MUST. Since cancer in all its forms, means that the immune system has given up (meaning asleep), then it is but common sense to wake up the immune system back to fighting mode. Transfer Factor focuses on the immune system's T-Lymphocytes or Killer T-Cells. "The T-Lymphocytes are the Ultimate Killing Machine of the Immune System" according to Dr. Jose Panopio, Surgeon, in his book "Transfer Factor, The Miracle Immunoresuscitator, Mystery Unveiled". With an Inducer Fraction property, Transfer Factor triggers a general state of readiness or induce a cell-mediated immune response via the Killer T-Cells, which are the immune cells of the last recourse and the weapon of mass destruction of malignant tumor cells. Transfer Factor, the phenomenal masterpiece of the immune system, the only supplement in the world made by the immune system for the immune system can wake up or activate the immune system by 437% immune activation, meaning it can kill 97% of cancer cells within 24-48 hours (in vitro or laboratory test). In the human body, 3,500 clinical tests were done on several types of cancer e.g. breast cancer, prostate cancer, lung cancer, leukemia, ovarian cancer, colon cancer, naso-pharyngeal cancer, sezary syndrome (cancer of the blood and skin), brain tumors, etc., and these patients were in various stages (stages 1-4), and healing occurred within 3-6 months (declared cancer-free). What chemotheraphy can not reach, the immune system can. Example, the brain, it has a blood brain barrier,which prevents chemo from passing through, so Transfer Factor can help and will take care of the rest when it come to metastasis in the brain since the Killer T-Cells are authorized to go all over the body including the brain. TF is also taken with regular exercise, proper diet e.g. Riovida juice, low sugar, no-meat, lots of fruits and vegetables; digestive enzymes and multi-vitamins and lots of positive thinking and positive attitude, one can experience complete restoration.
A Natural Killer Cell (Left) attacks Cancer Cells (Right) : an actual picture According to Wikipedia, "Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of cells display the traits of uncontrolled growth (growth and division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, do not invade or metastasize. Most cancers form a tumor but some, like leukemia, do not.
Cancer may affect people at all ages, even fetuses, but risk for the more common varieties tends to increase with age.[1] Cancer causes about 13% of all deaths.[2] According to the American Cancer Society, 7.6 million people died from cancer in the world during 2007.[3] Apart from humans, forms of cancer may affect other animals and plants.
Nearly all cancers are caused by abnormalities in the genetic material of the transformed cells. These abnormalities may be due to the effects of carcinogens, such as tobacco smoke, radiation, chemicals, or infectious agents. Other cancer-promoting genetic abnormalities may be randomly acquired through errors in DNA replication, or are inherited, and thus present in all cells from birth. Complex interactions between carcinogens and the host genome may explain why only some develop cancer after exposure to a known carcinogen. New aspects of the genetics of cancer pathogenesis, such as DNA methylation, and microRNAs are increasingly being recognized as important.
Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting oncogenes are often activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments. Tumor suppressor genes are often inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system."
Ref: http://en.wikipedia.org/wiki/Cancer
For the sake of my layman readers, let me simplify this illustation of how cancer starts. Since the human body's chemical composition includes Hydrogen (H), Oxygen (O), Carbon (C) and Nitrogen (N), let's talk about just one very important element, Oxygen. For example, one of the elements, inside the human cell, are two molecules of oxygen, which separates when subjected to stress by free radicals or other factors e.g. tobacco, pollution, toxins, worries, alcohol, drugs, others. Thus, 02 becomes 01 and 01. 01 can not survive being alone or it will die, so it joins another healthy cell 02, thus, forming 03. This formation becomes the start of cell mutation, the beginnings of cell distortion. This can be a cyst, then a tumor and then cancer.
"An atom with a single electron in its outermost orbital is known as a free radical. Free radicals are highly reactive and short-lived. In organism terms, they are responsible for cellular breakdown. Sun damage is a classic example of free radicals acting on skin cells."
Ref: http://www.biology-online.org/9/1_chemical_composition.htm
NK Cells kill cancer cells. This drama is reenacted 10,000 times every day as cancer cells are formed and destroyed in a healthy person's body. If this activity stops, the cancer cells are free to grow and become a clinical case of cancer. The residue resulting from the destruction of cancer cells is measurable in the blood serum and is a valuable indicator of anti-cancer action in the body.
The 'T' cells are produced by the thymus gland. They become mirror images of invading organisms and become antibodies. A small population of these cells are already conformed to kill cancer cells. They are called NK (Natural Killer cells). They examine other cells for the presence of certain molecules that identify the cell as a tumor cell or a cell that is infected with a virus. If such a cell is found, the NK cell deploys a tentacle with venom sacks and attaches to the suspect cell. It then reaches out with another tentacle to search for an 'off switch', a flag that tells the NK cell to back off and not kill the cell. If such a flag is not found, the NK cell blasts the target cell with particles, penetrating its outer shell and injects venom into the target cell. The venom pulsates in and out of the cell until it disintegrates in to small pieces.
Man used to be the hopeless victim of his circumstance. When Louis Pasteur developed the idea that bacteria cause disease and chemicals can kill bacteria, modern medicine was born. Ever since that day, we have struggled to develop chemicals in order to enhance our health. I do not wish to discredit the excellent work done by medical researchers in developing effective medicines. I remember in the 1920's and 1930's when mastoid infections were rampant and children were routinely given the disfiguring "mastoid operation" which left one ear laid back over the hole where the porous mastoid bone had been scraped out of the skull. One could scarcely go shopping without seeing one of these little boys or girls with one side of their skull caved in behind their ear. Chemical intervention by the means of antibiotics has delivered society from this scourge.
However, there is a philosophy which says that we live in an ocean of bacteria and viruses. It is not the microorganisms that cause disease, it is an inefficient immune system. We see the evidence of this truth constantly around us. One person in an office gets a very bad cold. The one sitting next to him doesn't get a sniffle. Certainly both were exposed to the same microorganisms. What is the difference? It is in the differences between their immune systems, isn't it? That's why we get a flu shot, to build up our immune system against the infection. The immune system destroys cells foreign to the body.
A popular expression in one area of the alternative medical treatment of cancer is this; "All cancer is the result of an immune system that didn't destroy mutant cells" Obviously, cancer cells are foreign to the body. The immune system of a healthy person destroys "10,000" mutated (cancer) cells every day. When this defense ceases, the cancer can multiply and become a clinical case of cancer.
Medical interventions such as chemotherapy and radiation therapy on cancer patients are aimed at destroying cancer cells, but that also kills the good immune cells such as natural killer cells, Killer T-Cells, Macrophages, etc. These good army network of immune system cells are killed in these therapies, therefore it weakens the patients' immune system. These can render the patient helpless against foreign invaders such as microbes, fungi, virus and bacteria and other pathogens. This explains why most people with cancer die of complications rather than from cancer.
Here is where Transfer Factor is truly a MUST! Transfer Factor teaches the immune system cells to locate and kill malignant cells and all foreign invaders of the human body, no exceptions. It has the ability to recognize all pathogens and direct these elite army of good cells e.g. the Ultimate "Killer Tc Cells' , Macrophages, NK Cells, etc to combat it instantly. Transfer Factor's mechanism of action is similar to the mechanism of action of a vaccine, however, its faster than vaccine as it is programmed to mirror specific antigens within the body in just 2 hours. Vaccines take several doses that would build the cell-mediated immunity from 2 months to 6 months.
On top of this, Transfer Factor has many other abilities still beyond our comprehension. It has a very wide spectrum of capabilities to educate, enhance and balance the immune system that no drug can do nor any vitamins, herb or antioxidants can ever come close in this lifetime.
PROPERTIES OF TRANSFER FACTOR (3 FRACTIONS):
1. INDUCER FRACTION:
TRIGGERS A GENERAL STATE OF READINESS IN THE IMMUNE SYSTEM
2. ANTIGEN SPECIFIC FRACTION:
AN ARRAY OF CRITICAL TAGS USED BY THE IMMUNE SYSTEM TO IDENTIFY A HOST OF ENEMY MICROBES
3. SUPPRESSOR FRACTION:
DOWN-REGULATES THE IMMUNE RESPONSE ONCE THE THREAT IS DEFEATED
[Please click on the above illustration for full view]
[Please click on the above illustration for full view] 
Above Clinical Study by Daryll See, M.D., Director
Institute of Longevity Medicine CA USA
Institute of Longevity Medicine CA USA
6. LEUKEMIA
In the United States about 27,000 adults and 2,000 children are diagnosed each year with leukemia, a cancer of the white blood cells (WBCs). While exposure to radiation, benzene, and some anticancer drugs have been shown to increase the risk of developing leukemia, and a few cases are associated with genetic disorders or rare viral infections, the cause of most leukemias is not known.
What is it?
Leukemia is a bone marrow disorder that arises when one abnormal white blood cell begins to continuously replicate itself. These cells do not function normally, they do not fight infection as they should, and they do not die at the same rate as other WBCs. As they accumulate, they inhibit the production of the other normal blood cells in the marrow, leading to anemia, bleeding, and recurrent infections. Over time, the leukemic cells spread through the bloodstream where they continue to divide, sometimes forming tumors and damaging organs such as the kidney and liver. Since the spleen is responsible for filtering the blood and destroying old cells, it may become enlarged and swollen with the abnormal cells, as can the liver and lymph nodes. If the cells reach the central nervous system and build up in the cerebrospinal fluid that supports the brain and spinal column, they can cause headaches and seizures.
The bone marrow, located in the soft center of the body's larger bones, produces precursors (immature versions) of red blood cells, platelets, and five different kinds of white blood cells. The most immature of these is called a blast. Most of these blood cells mature in the bone marrow before being released into the bloodstream. The WBCs created are grouped into two main categories: lymphocytes and myelocytes (also called granulocytes for the granules found inside the cell). Myelocytes (which include neutrophils, basophils, eosinophils, and monocytes) circulate in the blood, killing and digesting bacteria. Lymphocytes, which are found in both the blood stream and the lymphatic system, coordinate the immune response and produce antibodies. Leukemia arises from one of these white blood cells. It is categorized both by the type of WBC involved and by how quickly it progresses. Although expanded classifications of the disease exist, the main types of leukemia can be grouped as:
* Acute lymphocytic leukemia (ALL). This is a rapidly developing disease that is characterized by large numbers of immature lymphocytes. It is the most common type of leukemia found in children, although it affects both children and adults (usually adults age 65 and older).
* Chronic lymphocytic leukemia (CLL). This disease progresses more slowly and is characterized by a mixture of mature and immature lymphocytes. It tends to be found in those over the age of 55 or 60.
* Acute myeloid (myelocytic) leukemia (AML). Affecting people of all ages, this disease is characterized by production of large numbers of immature granulocyte myeloid cells (immature neutrophils -- the most common, monocytes, basophils, eosinophils, platelets or red blood cells) that replace other normal cells in the marrow.
* Chronic myelogenous (myelocytic or myeloid) leukemia (CML). Chronic myelogenous leukemia is rare in children. It is an acquired condition that begins in an immature stem cell in the bone marrow when pieces from two chromosomes (9 and 22) break off and switch places (translocation). This results in an altered, fused gene (bcr/abl) on chromosome 22 that produces a protein called tyrosine kinase that affects cell growth regulation. This leads to an overproduction of granulocytic white blood cells, many with the bcr/abl translocation, and the presence of both mature and immature cells in the bloodstream.
LOCAL TESTIMONY ON LEUKEMIA USING TRANSFER FACTOR:
A 21 year old woman from Palawan with Stage 1 Leukemia took Transfer Factor Cardio with only 2 capsules a day and after one month, she was declared healthy and leukemia-free.
BLOOD TEST REFERENCE CHART
7. CANCER
A. BREAST CANCER
A 43 year old woman, Samantha, with Breast Cancer (Grade II) called me on May 17, 2008 when she heard me talk over DZEC's "Basta Natural" Radio Program (Sundays @ 7:15-7:30PM). Her Pathological Diagnosis: Breast mass, Left, Excision Biopsy: Infiltrating Ductal Carcinoma, Tumor Size: 1.5 cm . Gross and Microscopic Description: The specimen submitted consists of an ovoid, grayish, doughy mass measuring 1.5 x 1.0 x 1.0 cm. Cut sections reveal a brown solid surface RSEB1. Sections of the breast mass reveal an infiltrating ductal mass carcinoma characterized by nests of atypical cells forming minimal tubular structures. These tumor cells feature enlarged vesicular nuclei with prominent nucleoli and scanty eosinophilic cytoplasm. Some nuclei appear hyperchromatic. The stroma shows fibrosis.
The doctors recommended removal of breast by surgery.
After I talked to Samantha on May 20, 2008 , she and her husband decided not to undergo surgery nor chemotheraphy, but just take transfer factor and so I gave a mega dose of : Transfer Factor Tri-Factor Plus (3 caps 3 x a day), Transfer Factor Tri-Factor Formula (2 caps 3 x a day) and TF Riovida (30 ml 3 x a day).
On August 2, 2008 (less than 3 months only) her ultra sound shows an amazing Cancer Free result. (Please see lab test results below)
Today, Samantha is all out helping others get back their health by promoting Transfer Factor likewise. Her first patient was cured of COPD (Chronic Obstructive Pulmonary Disease) after 2 months.
The rest is history.
Before Transfer Factor (April 2008)
After Transfer Factor (August 2, 2008)
Cancer-Free
B. PROSTATE CANCER STAGE 4An 82 year old man was dying (1 week to live in NKI) in 2005 due to Stage 4 Prostate Cancer, with metastasis in the lungs plus Severe Pneumonia. All three doctors signed a waiver because it was the end of the line. I gave this man Transfer Factor Plus 4 caps 3 x a day, Transfer Factor Advanced 2 caps 3 x a day and TF Riovida 40 ml 3 x a day. He could not take anything by mouth so we gave Transfer Factor via NGT and also via sublingual, wiping the tongue and areas around it daily. Amazingly, in just 11 days, he stood up and walked home. In 3 months he was declared Cancer-Free as proven in the MRI test. Today, after 4 years, I checked on him and he is enjoying fishing and living the good life.
C. CYSTIC BREAST
A 40 year old woman from General Santos with a cyst in her breast below the nipple took Transfer Factor Plus 2 capsules 3 times a day and in two days the cyst dissolved completely. She took it one hour before every meal and she practiced sleeping at 11pm with lights off. Then after two days she was amazed that the cyst was gone.
8. LEPROSY & SKIN ASTHMA/OTHERS
TRANSFER FACTOR is very effective adjuvant as Supportive Therapy for Leprosy Patients who are WHO, World Health Organization, Drug Resistant Case with Lepra Reaction and those suffering from Severe Skin Asthma according Dr. Ma. Luisa Abad-Venida, M.D., FPDS,- CONSULTANT DERMATOLOGIST, FORMER CHAIR OF THE DEPT OF DERMATOLOGY, JOSE REYES MEMORIAL MEDICAL CTR & PRESIDENT of the SKIN RESEARCH FOUNDATION OF THE PHIIPPINES. [You may contact her at her Clinic- Telephone:(632)7116703, 9205041 or 9217252, Mobile: (63)9178173065]
Dr. Venida has tested Transfer Factor in combination with prescribed medication on several leprosy and severe skin asthma patients and she can attest to its effectiveness in improving the effects of standard therapeutic regimen. So Transfer Factor must be used in combination with approved regimen.
CASE STUDIES USING TRANSFER FACTOR
ON LEPROSY WITH LEPRA REACTION
BY DR. MA. LUISA ABAD-VENIDA, M.D.
Dx. Lepromatous Leprosy,
WHO Drug Resistant Case
C.,21 yr old male
Tx.
Lymecycline 30 mg bid
Transfer Factor Plus 9 capsules a day
ON LEPROSY WITH LEPRA REACTION
BY DR. MA. LUISA ABAD-VENIDA, M.D.
Dx. Lepromatous Leprosy,
WHO Drug Resistant Case
C.,21 yr old male
Tx.
Lymecycline 30 mg bid
Transfer Factor Plus 9 capsules a day
The Use of Transfer Factor in Lepra Reaction by Dr. Ma. Luisa Abad-Venida, M.D.
Introduction:
The decline in registered prevalence of leprosy worldwide stimulated the recent policy changes within the World Health Organization. The emphasis was shifted from tackling leprosy as a public health issue to sustaining quality services for people affected by the disease; to prevent deformities and thus remove the stigma attached to it. Deformities in leprosy are due to lepra reaction that damages the peripheral nerves leading to paralysis of the affected muscle or loss of function of skin appendages. Lepra reaction may occur before treatment, but more so during treatment and continuing intermittently or continuously until the body has totally eliminated the mycobacterium debris from the body. Prompt and proper treatment of lepra reaction is critical in preventing deformities. The most common treatment option available is corticosteroid that acts as T-cell suppressor(1,2,3,4,5) Although steroid is very effective in treating lepra reaction, its chronic use in cases of severe lepra reaction poses the problem of further compromising the cell mediated immunity status of patients in the lepromatous spectrum, encouraging emergence of resistant strains and/or the accompanying problem of steroid toxicity.
In the Philippines
The use of Transfer Factor led to the successful recovery of the three cases of severe lepra reaction that have already completed MDT treatment.
CASE REPORTS
Case 1
A 15 year old male child from Malabon City, in type II lepra reaction, was diagnosed with lepromatous leprosy in 2003 at the age of 12 years old, with an average bacteriologic index (BI) of 4.6+, was given MDT on 1Jan03-31May03 and 17Jun05-30April06. Lepra reaction developed on his 2nd month of MDT, corticosteroid was started following the WHO recommendation. His intake of steroid beyond 12 weeks was either prescribed or as self medication. He was also prescribed NSAIDs, Colchicines and Squalene.(fig 1.1) Between May 2004 BI 2.8+ and May05 BI 2.6 with slackened drop in average BI and chronic use of steroid, coupled with high WBC 32.38 and high alkaline phosphatase 270 (44-155) it was deemed necessary to reinstitute another course of MDT under close monitoring. In March 06, there was worsening of the symptoms manifested as high grade fever 39C, joint pains, body malaise, increased erythema, swelling of digits of both hands and elevation and tenderness of plaques. There was also muscle weakness as he was incapable of feeding himself and writing his assignment.(fig.1.2 and 1.3)
With a BI 1.4+, an impression of steroid toxicity and or dapsone syndrome with lepra reaction required hospitalization, discontinue all medications and initiate supportive therapy. Transfer Factor 600mg TID was started initially, on his 3rd hospital day, joint pains disappeared together with body malaise and fever. Plaques and hand swelling gradually diminished and he was discharged after 5 days confinement. Home medications were Transfer Factor in supervised doses, Vitamin B complex, colchicines and petroleum jelly. Patient condition continued to improve after consuming 108,000 mg pure Transfer Factor and 54,000 mg plus cordyvant Transfer factors.(fig 1.4) AFS turned negative in 2007.
Case 2 (See Treatment Graph Above)
A 21 year old male from Bulacan, was diagnosed with lepromatous leprosy in 2004. His condition started as numbness on the R elbow 15 years prior to consult (PTC) but did not sought treatment. He was 13 years old when he was given MDT-MB but took only 3 blister packs and stopped because of improvement. For about 3 years PTC, he was suffering from increasing number of patches in his body and appearance of nodules on the face and earlobes before finally coming to our institution, and, with his younger brother who has the same problem.
His average BI 4.5+, highest on R earlobe 6+ solid, on admission, persisted from 4Nov04-25Sept05 until the end of his regular MDT-MB treatment. At this time, he complained of myalgia, dizziness and easy fatigability. CBC revealed severe anemia Hgb 77. Drug resistance to MDT and/or Dapsone syndrome was considered and so Ofloxacin 400mg OD 5Sept05-3Feb06 (fig 2.1) was added to his regimen with clofazimine 200mg daily in tapering dose with Dapsone was removed from the regimen.
He developed lepra reaction during his 2nd blister pack and was prescribed corticosteroid following the WHO recommendation, NSAIDs and colchicine plus supportive medications of aluminum MgSO4, Vit D, Calcium and B complex. (fig 2.2) His signs and symptoms were generalized erythematous plaques, nodules, vesicles, ulcers, crusting, joint pains, nerve tenderness and fever.
In Feb 2006, with a persistently high average BI 4.5+ (fig 2.1) despite the 5 months treatment of Modified MDT-MB, and worsening skin lesions, accompanied by chills and fever, joint pains and deteriorating liver function SGPT 68.5(0-38) and SGOT 222.9(10-40) it was recommended by Internal Medicine to totally discontinue present Modified MDT medications. Multiple drug resistance was considered with lepra reaction. Alternative drugs were given in Mar 06 namely Transfer Factor 300mg with cordyvants TID and Lymecycline 600mg OD for 4 months. Solid M. leprae bacillis on smears became granulated after 1 month dose and thereafter. (fig 2.3) Prednisone was tapered till 5mg every other day but self- medicated as necessary, when new ENL lesions and joint pains were noted occasionally. There was also irregular intake of Transfer Factor because of financial constraints. In Nov 07, noting the presence of one solid bacilli on smear, and an average BI 4+, he was given another 3 months course of Lymecycline 600mg OD together with more regular intake of full doses of Transfer Factor Plus cordyvant. AFS as of Feb 08 was average BI 1+. ( fig 2.4). The patient will be maintained on Transfer Factor 300mg TID plus cordyvant till AFS negative. As of this writing, he still suffers of few ENL lesions. (fig 2.5)
Case 3
A 22 year old male from Bulacan was diagnosed with Borderline leprosy in type II lepra reaction in 1Mar06. He was given MDT-MB treatment from 4April06-8March07 and Prednisone 40mg following the WHO recommendation with Clofazimine, Colchicine, Extra virgin coconut oil (EVCO), and Ranitidine. He was never totally off prednisone when in Oct. 30, 2007 , he was brought to JRRMMC, wheelchair borne, unable to walk because of severe pain and swelling of both feet with deep necrotic ulcers. (fig 3.1) There was also ulceration on his knee. There was associated nausea and L abdominal pain. His baseline AFS was average BI 3+ and Ave. BI 2+ at the end of MDT-MB treatment.
His diagnosis was Lucio Phenomenon, released from treatment (RFT). Transfer factor 300mg TID plus cordyvants was prescribed as well as gradual tapering of steroid. Debridement with sandwich dressing was done on 2 weekly follow-ups and he was able to walk and go up the stairs on his 3rd week. His latest ave.BI is .5+ as of Feb08. He will continue to take transfer factor plus until he is AFS negative and aim at removing prednisone 5mg q2d as security blanket treatment.
Advances in civilization, scientific and technical progress, achievements in medicine, have not helped reduce infectious diseases; rather there are newer groups of infections that are attacking people. Leprosy, a disease known to men, existing even before Christ have long been recognized to be due to poor cellular defense against Mycobacterium leprae among advanced stages. 90% of Filipino patients with leprosy suffers from the multibacillary form of the 2,517 new cases detected in 2006, which brings to fore the high possibility of leprae reaction to >50%.
Multi-drug therapy (MDT), a regimen recommended by WHO was introduced in the Philippines
The problem of logistics, compliance, drug intolerance and side effects to MDT-MB treatment, points to an urgent need for a supportive approach like immunotherapy. Immunotherapy has been found to shorten the course of treatment and clearance ensuring early relief from lepra reaction.
Lepra reactions are episodes of sudden increase in the immune activity of the disease versus the host. There are 2 forms of lepra reaction, type I being less severe compared to type II lepra reaction that occurs in multibacillary forms. The treatment of reactions is based on suppression of inflammation and WHO recommends the use of prednisone to do this.A high dose of prednisone 40-60mg daily taken for 12 weeks may result in several undesirable effects. These are Cushing’s syndrome, steroid induced diabetes, osteoporosis, hypertension, psychosis, depression, striae and increased susceptibility to infection especially tuberculosis. It has been reported that in borderline (BB) treatment of lepra reaction takes weeks, borderline-lepromatous (BL) wks and lepromatous leprosy (LL) wks. In these patients, there is high antibody response and the dominant cytokine circulating in their body are IL4 which promotes B cell growth and differentiation and IL10 which inhibits ThI cytokine production. Leprosy is one of infectious diseases that manifest the Th1-Th2 paradigm shift with progressive evolution of the disease from tuberculoid (TT) form exhibiting the Th1 status to lepromatous (LL) form exhibiting the Th2 status. With this basic information in mind, an important enhancement against M.leprae in our general immune system should be one of our therapeutic goals.
Transfer Factor as was used to supplement the treatment in these 3 cases has been used to effectively treat a wide range of diseases. Transfer Factor is an immune modulator. The main function of these peptides in the body is to provide immune protection against microbes (bacteria, viruses, fungi, protozoa), cancerous cells and other antigens capable of disturbing vital processes in the body. It stimulates the cellular arm of the immune system (killer lymphocytes), activates immune cytokine synthesis and regulates immune function. An evaluation of Transfer Factor as immunotherapy for patients with lepromatous leprosy was first used by Bullock, using whole lymphocytes from donors with delayed hypersensitivity to antigens of mycobacterium leprae were employed to reconstitute delayed hypersensitivity in nine patients with anergic leprosy. Six of seven converted from anergy to delayed hypersensitivity response to m. leprae antigens. Two of 3 patients showed an increase in perivascular lymphocytic infiltration in the post-transfer skin test biopsy site. Delayed hypersensitivity reactions to M. leprae antigens can be produced, with lymphocytes or their extracts, in patients with anergic leprosy. In a study by Fabre of Mexico, in his study of Transfer Factor as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. When BALB/c mice are infected via trachea with M. tuberculosis, H37Rv, there is an initial phase of partial resistance dominated by Th-1 type cytokines plus tumor necrosis factor-alpha (TNFa) and the inducible isoform of nitric oxide synthetase (iNOS) followed by a phase of progressive disease characterized by increasing expression of IL-4, diminished expression of TNFa and iNOS and low DTH. Animals in this late progressive phase of the disease were treated with different doses of transfer factor ( one injection per week) obtained from spleen. The peak of immune protection in this animal model is reached on day 21(11)
Since its discovery by Sherwood Lawrence, more than 50 years ago, the therapeutic and prophylactic applications have been most important and interesting aspects of Transfer Factor. It has been found to be very effective in those diseases in which CMI plays a relevant role in protection and control of the disease , such as viral infections (herpes simplex, varicella zoster), intracellular bacterial diseases (tuberculosis, leprosy) and parasitic infections (leishmaniasis, toxoplasmosis), as well as in immunodeficiencies (chronic granulomatosis, Wiscott Aldrich syndrome and some types of cancer. Transfer Factor (TF) are protein that transfer the ability to express cell mediated immunity from immune donors to non-immune recipients. TF treatment were found to selectively affects cytokine production in response to antigenic stimulation.(12)
Transfer factors are tiny molecules also found in colostrum which provides immune knowledge from mother’s immune system to her baby used in fighting outside threats. By transferring information from cell to cell, transfer factors serve as “teacher” to the new cells, ensuring a strong immune system capable of surviving, and thriving in its new environment. Transfer factor are not species-specific and can therefore be extracted from any mammal and then be given to another mammal with the same efficacy. Transfer factor naturally supports the body’s immune system, communicating immune information more efficiently among the cells in the body, and ultimately enhancing the body’s ability to withstand attacks on its health.
Transfer Factor TM was tested for its ability to increase Natural Killer Cell (NK) activity. Peripheral blood mononuclear cells (PBMC) isolated from human volunteers showed boosting of NK cell activity by 103% above normal immune response. NK cells are important in strengthening and supporting the immune system . In advanced stage leprosy (LL)where there is poor to absent CMI activity, it was found by Bullock, etal the positive effect of Transfer factor in anergic leprosy, it was also found by Katoch etal the early clearance of bacilli in LL patients given MDT and Transfer Factor.
References:
1). WHO Expert Committee on Leprosy. Seventh Report. WHO Technical Report Series No. 874. World Health Organization, Geneva
2). Briton, WJ. The management of leprosy reversal reactions (Editorial). Lepr Rev, 1998: 69: 225-234.
3). Rose P, Waters MF, Reversal reactions in leprosy and their management (Editorial). Kepr Rev, 1991; 62: 121-131.
4). Naafs B. Treatment of reactions and nerve damage. Int J Lepr, 1996: 64:S21-28.
5). Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the Leprosy Control Program of the All Africa Leprosy and rehabilitation Training Center (ALERT) in Ethiopia
6). Ji, B., E. G. Perani, C. Petinom and J. H. Grosset. 1996 Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother, 42(1998)1115-1120. 2. JI, B., etal Bactericidal activities of combination of new drugs against mycobacterium leprae in nude mice. Antimicrof.Ag Chemother, 40:393-399.
7). Ji, B., P. Jamet, S. Sow, E.G. Perani, I. Traore, and J.H. Grosset. 1997 High relapse rate among lepromatous leprosy patients treated with Rifampicin plus Ofloxacin daily for 4 weeks. Antimicrob Agents Chemother, 41: 1953-1956.
8). Lawrence
9). Bullock, W.E., Fields, J.P. amd Bandvias M.W.1972 Am evaluation of transfer factor as immunotherapy for patients with lepromatous leprosy. New Eng J Med. 287:10-53.
10). Katoch 1986 Combination drug therapy
11). Fabre R A, Perez T M, Aguilar, L D, Rangel M J, Estrada-Garcia I, Hernandez-Pando R, and Estrada Parra S. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis 2004 Clin Exp Immunol 136(2): 215-223.
12). Alvarez-Thull L, Kirkpatrick C H. Profiles of cytokine production in recipients of transfer factors. 1996 Biotherapy 9(1-3) 55-9
13). Fitzpatrick etc
Click here to listen to Dr. Ma. Luisa Venida's talk on Transfer Factor & Leprosy on DZEC 1062Khz.
9. HIV/ AIDS
In its Methodoligical Letter (Moscow 2004), The Ministry of Health and Social Development of the Russian Federation published the following :
"Acquired Immunorehabilitation Syndrome (AIDS) is one of the most serious problems confronting medicine. For HIV patients immune modulation therapy (i.e. the restoration of normal immune function) is aimed altered immune mechanisms and at the pathogenic agent(s).
The results of studies conducted showed that TRANSFER FACTOR (TF) PLUS treatment significantly improved the immune status of HIV patients. The product also proved useful in other aspects of therapy as for example the level of circulating immune complexes (CIC) decreased to normal values in 50% of patients receiving TF PLUS."
In the XIth International Congress on TransferFactor held in Monterrey Nuevo Le
on, Mexico, 1999, an article below was presented:
"TITLE: 25 YEARS OF CLINICAL EXPERIENCE WITH TRANSFER FACTOR
AUTHORS: Giancarlo Pizza, Caterina de Vinci, Aldopaolo Palareti, Dimitri Viza
INSTITUTION: Immunotherapy Unit, Div. of Urology, S. Orsols-Malpigi Hospital Bologna, Italy
ABSTRACTS:
Patients. From April 1974 to Hanauary 1999, using TF produced in our laboratories, we treated a total of 1647 patients (pts) suffering from persistent viral infections viz. hepatitis, herpes, herpes zoster, giant condyloma acuminatum, conjunctivitis, herpes keratitis and keratouveitis, (439 pts), cancer, viz. Prostate, lung, renal metastatic, transitional cell carcinoma of the bladder (TCCB), EBV-related naso-pharyngeal carcinoma (NPC), gastrointestinal (GIT), ovary, uterus, Burkitt's lymphoma, breast, glioblastoma (643 pts), recurrent cystitis and candidiasis (287 pts), chronic fatigue syndrome (74 pts). AIDS (51 pts) and /or various congenital and (/or autoimmune disorders, e.g. retinitis pigmentosa, chorioretinitis, uveitis, Bechet's syndrome and Lapeyronie's disease (153 pts)."
Reference: www.biotransfer.org
In the ABSTRACTS OF THE COMMUNICATIONS PRESENTED AT THE XTH INTERNATIONAL SYMPOSIUM ON TRANSFER FACTOR, HELD IN BOLOGNA (ITALY) JUNE 22-24, 1995:
"AIDS AND TRANSFER FACTOR: MYTHS, CERTAINTIES AND REALITIES
by Dimitri Viza
Laboratoire d'Immunobiologie, URA 1294 CNRS, Faculté de Médecine, Paris, France
At the end of the 20th century, the triumph of biology is as indisputable as that of physics was at the end of the 19th century, and so is the might of the inductive thought. Virtually all diseases have been seemingly conquered and HIV, the cause of AIDS, has been fully described ten years after the onset of the epidemic. However, the triumph of biological science is far from being complete. The toll of several diseases, such as cancer, continues to rise and the pathogenesis of AIDS remains elusive.
In the realm of inductive science, the dominant paradigm can seldom be challenged in a frontal attack, especially when it is apparently successful, and only what Kuhn calls "scientific revolutions" can overthrow it. Thus, it is hardly surprising that the concept of transfer factor is considered with contempt and the existence of the moiety improbable: over forty years after the introduction of the concept, not only its molecular structure remains unknown, but also its putative mode of action contravenes dogmas of both immunology and molecular biology. And when facts challenge established dogmas, be in religion, philosophy or science, they must be suppressed. Thus, results of heterodox research become henceforth nisi - i.e., valid unless cause is shown for rescinding them, because they challenge the prevalent paradigm. However, when observations pertain to lethal disorders, their suppression in the name of dogmas may become criminal. Because of the failure of medical science to manage the AIDS pandemic, transfer factor, which has been successfully used for treating or preventing viral infections, may today overcome a priori prejudice and rejection more swiftly. In science, as in life, certainties always end up by dying and Copernicus' vision by replacing that of Ptolemy."
Reference: http://www.biotransfer.org/art03.html 8. HOW TO TAKE TRANSFER FACTOR (TF)
In its Methodoligical Letter (Moscow 2004), The Ministry of Health and Social Development of the Russian Federation has published the following methods of administering TF Use Recommended Doses:
"The developments of rational and effective regiments for the use of TF in various pathological conditions have been demonstrated. Both literature data and the results of clinical studies presented in this paper give justification for recommending regimes for TF and TF PLUS use in initial and anti-relapses therapy of somatic and in infectious diseases (table 1).
The conventional scheme of TF use is: · For the prevention of seasonal diseases (spring, autumn) connected with the weakening of the immune system -1 capsule 3 times daily for 30 days;
· In acute infections at the beginning of a disease - 2 capsules 3 times daily for not less than 7 days." | Desease | Treatment Proceedures | Dose | Duration of Treatment |
| 1 | 2 | 3 | 4 |
| HIV | TF+ | 1 cap. 3 times a daily | 14 days repeated with immunogramm monitoring |
| Acute Viral Hepatitis B (sluggish or protracted course) | TF | 1 cap. 3 times a daily | 14 days individual repeated courses during follow-up study |
| Chronic viral hepatitis B and C | TF or TF+ | 1 cap. 3 times a daily | For 14 days each month for the first three. Repeated courses for 14 days, 1 capsule 3 times a daily, monitored by biochemical analyses, liver ultrasound investigation once every 2-3 month. |
| Hematogenic Osteomyelitis & Immunodeficiency – 1st Type | TF & basic antibacterial therapy | 2 caps. 3 times daily | 14 days before surgery and 2 month after surgery |
| In case of immunodeficiency persistence after a 2 month treatment | TF | 1 cap. 3 times a daily | Two month |
| Chronic Osteomyelitis aggravation | TF and basic treatment | 2 caps. 3 times daily | 1 week before surgery and 1 month after surgery |
| Opisthorchiasis | TF or TF+ After antihelminthic treatment and bilthricide | 1-2 caps. 3 times daily | 7 days repeated courses in case of persistence of immunopathological processes manifestations (arthralgia, vasculitis) |
| Acute Urogenital Chlamydiosis | TF+ and antibiotic | 1 cap. 3 times a daily | 10 days |
| Chronic Urogenital Chlamydiosis (complaints and clinical manifestations lasting for more than 2 month) | TF or TF+ and antibiotic | 2 caps. 3 times daily/1 caps. 3 times daily | 10 days and for 2 month after the end of the basic treatment (antibacterial therapy aimed at prevention of complications) |
| The involvement of internal reproductive organs (as complications of chronic urogenital chlamydiosis) | TF+ complex treatment along with various groups of drugs, as well as physio- and restoration treatments | 2 caps. 3 times daily 1 cap. 3 times daily | 10 days during a process aggravation 10 days as a preventive measure the frequency of TF use depends on the extension and severity of the process, as well as the presence of a secondary immunodefiency and as a preventive measure and varies from 2 to 4 times a year |
| Psoriasis, Atopic Dermatitis | TF | 1 cap. 3 times daily | 14-21 days; repeated courses and during unfavourable seasons of the year |
| Gastric Cancer after Surgery | TF+ | 1 cap. 2 times daily | 30 days minimal frequency of repeated courses: 2 month |
| Duodenal Ulcer: - during_eradication - after_eradication - anti-relapses treatment | TF+ | 2 caps. 3 times daily 1 cap. 3 times daily 1 cap. 3 times daily | 7-10 days until the end of a month (20-23 days) For 1 month early in spring and late autumn |
10. CLINICAL STUDIES : TRANSFER FACTOR AS IMMUNOTHERAPY AND SUPPLEMENT OF CHEMOTHERAPY IN EXPERIMENTAL PULMONARY TUBERCULOSIS
AU: R. A. FABRE, T. M. PÉREZ, L. D. AGUILAR, M. J. RANGEL, I. ESTRADA-GARCÌA, R. HERNÁNDEZ-PANDO, S. ESTRADA PARRA
TI: Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis
SO: Clinical & Experimental Immunology
VL: 136
NO: 2
PG: 215-223
YR: 2004
ON: 1365-2249
PN: 0009-9104
AD: Department of Immunology, National School of Biological Sciences, National Polytechnical Institute and ; Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mxico
DOI: 10.1111/j.1365-2249.2004.02454.x
US: http://dx.doi.org/10.1111/j.1365-2249.2004.02454.x
AB: Problems of logistics, compliance and drug resistance point to an urgent need for immunotherapeutic strategies capable of shortening the current six month antibiotic regimens used to treat tuberculosis. One potential immunotherapeutic agent is transfer factors. Transfer factors (TF) are low molecular weight dialysable products from immune cells which transmit the ability to express delayed-type hypersensitivity (DTH) and cell mediated immunity from sensitized donors to nonimmune recipients. In this study we determined the efficiency of TF as immunotherapy to treat experimental tuberculosis. When BALB/c mice are infected via the trachea with Mycobacterium tuberculosis H37Rv there is an initial phase of partial resistance dominated by Th-1 type cytokines plus tumour necrosis factor-alpha (TNF03B1) and the inducible isoform of nitric oxide synthase (iNOS), followed by a phase of progressive disease characterized by increasing expression of IL-4, diminished expression of TNF03B1 and iNOS, and low DTH. Animals in this late progressive phase of the disease (day 60) were treated with different doses of TF (one injection per week) obtained from spleen cells when the peak of immune protection in this animal model is reached (day 21), or with different doses of TF from peripheral leucocytes of PPD + healthy subjects. We show here that the treatment with murine or human TF restored the expression of Th-1 cytokines, TNF03B1 and iNOS provoking inhibition of bacterial proliferation and significant increase of DTH and survival. This beneficial effect was dose dependent. Interestingly, murine TF in combination with conventional chemotherapy had a synergistic effect producing significant faster elimination of lung bacteria loads than chemotherapy alone.
MORE CLINICAL STUDIES
The following five articles are from the IX National Congress of Dietologists and Nutriologists that took place in Moscow, Russia December 3-5 and published in Nutrition and Health. This National Scientific Practical Conference of Pediatric Nutritionalists was a divisional meeting of the Russian Academy of Medical Sciences.
A. Transfer Factor Classic Effectiveness in the Treatment of Patients with Opthalmotoxoplasmosis.
G.K. Zhumanbayeva, G.U. Alshinbayeva, M.G. Portnova, K.M. Baygabulova, I.N. Losiev, B.B. Utegenova, E.S. Seitakhmet. “Zhurek” clinic, Karaganda
We used a systemic approach to analyze the dynamics changes in patients treated for Opthalmotoxoplasmosis. The 1st group patients after receiving the regular treatment medicine
(rovamycin) did not manifest any significant changes in immune index correlations, except there was a significant increase in the neutrophilic immunity index that increased by 33.3%. Interrelations of immunity displayed a moderate degree of significance (28.6%, r≥0.5). After receiving Transfer Factor Classic in combination with rovamycin, the number of statistically significant correlations of immune index increased by 57.1% and the number of statistically
significant interrelations in neutrophil index increased to 47.6%. Correlations with only a moderate degree of significance (r≥0.5) occurred in 48% of the total number of all interrelations in this group. The 2nd group received Transfer Factor Classic in addition to rovamycin. This treatment regime proved especially beneficial to those with neurotoxoplasmosis and visual impairment, when compared to other existing methods of treatment, which are far less effective in these espects. The analysis performed after the combined treatment demonstrated a significant improvement in 87.5% of patients and moderate improvement in 12.5% of them. The combined treatment (rovamycin and Transfer Factor Classic) significantly increased the number of leukocytes by 21.5% with neutrophils up 31.1%; the number of T-lymphocytes increased by 46.1%; the content of “zero” lymphocytes decreased by 27.1% due mainly to the increase of T-helpers by 40.9%. The combined data for the group showed phagocytic activity of neutrophils increased by 52.3% and IgG level increased by 36.8%. The inclusion of Transfer Factor Classic also contributed to positive dynamics of primary, secondary, intermediate, summary and end point peroxide lipid oxidation (PLO) products (excluding ketodiens) and in restoring patients’ values to those of nominally healthy people. Thus, according to the dynamics of PLO-АОS (peroxide lipid oxidation - antioxidative system).
We concluded that this regiment of combined treatment, which includes Transfer Factor Classic, is the most effective method of opthalmotoxoplasmosis treatment that we have experienced in our clinic.
B. The Use of Transfer Factor as Alimentary Support of Specific Chemotherapy in Primary Multiresistant Tuberculosis.
I.G. Tsoy, A.M. Yesengelgiyeva. Kasakh Academy of Nutrition, Alma-Ata
Transfer Factor, a versatile natural peptide immunocorrectors, at oral dosages of 1 capsule 3 times daily for one month and Transfer Factor Plus at 1 capsule 3 times daily for one month was used in the treatment of patients suffering from primary drug resistant pulmonary tuberculosis
to such second line drugs as capreomycin, protionamid, ofloxacin, cecloserin. The patients demonstrated a significantly earlier disappearance of signs of toxification, cough, symptoms of respiratory failure and an acceleration of the process of temperature normalization.
The cessation of bacterial release, return to normal ESR (erythrocyte sedimentation rate) and moderation of leukocytosis were all of shorter duration as well. Frequency of the reparation process, development and resorption of pulmonary tissue infiltrates as well as shrinking and closure of decomposition cavities indicate the positive effect of this alimentary immunocorrector. With it we managed to eliminate the existing deleterious changes that had occurred in liver function and also to prevent the development of adverse reaction of intestinal microbiocenosis to these second line antituberculous drugs.
The use of Transfer Factor products contributed to the increase of what was an initially low numbers of CD3+ and CD4+ T cells, the number of T-regulatory and cytotoxic cells (CD8+) also changed significantly. The changes in the number of immunoregulatory T-cells resulted in significant increase in the initially low mean value of quantitative immunoregulatory index (CD4+/CD8+). In the test group the relative number of NK-cells (CD16+) reached those of the
control group. In most cases there were no statistically significant changes in the number of B-lymphocytes, which values being slightly elevated. According to the data of the leukocytes migration inhibition reaction there was a distinct increase in delayed sensitivity to tuberculin,
which was especially noticeable in the dynamics of the individual values. While evaluating humoral immunity we noted that the use of alimentary immunocorrectors contributed to the decrease of initially high levels of IgA, IgM and IgG, with the IgG numbers decreasing the most
significantly. As to the phagocytic system the neutrophilic leukocytes (NST-test) demonstrated greater bactericidal reserve.
C. The Role of the Biologically Active Supplement Transfer Factor in Increasing Preoperative Polychemotherapy Effectiveness in Breast Cancer and in Decreasing Side Effects.
I.G. Tsoy, M.I. Saktaganov, Kazakh Academy of Nutrition, Alma-Ata
We used Transfer Factor, a biologically active supplement produced by 4Life company, USA at dosages of 1 capsule 3 times daily for 1-3 courses of treatment in conjunction with aggressive polychemotherapy treatment of breast cancer patients. We used it to determine if it would decrease the major side effects (immunohematological effects in particular). A control group of matched subjects in age and clinical forms of the disease did not receive Transfer Factor.
The use of the transfer factor immunocorrector markedly contributed to the decrease in the frequency and the severity of common polychemotherapy complications such as toxification, nausea, vomiting, anorexia, taste change and intestinal function disturbances. The dynamics, as indicated by total blood count, showed a distinct protective effect of the Transfer Factor on red blood (erythrocytes number, hemoglobin, serum iron and ESR levels) and white blood (leuko- and lymphopenia) cells. As compared to the control group the test group patients also demonstrated less frequent and less pronounced polychemotherapy complications in terms of liver function (ALT, AST, GGT and gamma-glutamyltransferase), kidney function (total urinalysis, creatinine and urea levels), and chronic pyelonephritis aggravation and other functions and in blood serum total albumen and its fractions.
According to immunological monitoring assays the test group experienced a smaller decrease of relative and absolute number of total T-lymphocytes (CD3+) circulating in peripheral blood along with their helper-inductor subpopulation (CD4+) and cells expressing receptors to IL-2
(CD25+). The increases in T-lymphocytes of suppressors and killers phenotype (CD8+) in the test group are attributable to protective effect of Transfer Factor. The ratio CD4+/CD8+ (conventional quantitative immunoregulatory index) of the test group decreased less that for the control group during the course of polychemotherapy. Also, the decrease of natural killer cells (CD16+) in peripheral blood resulting from chemotherapy was less pronounced in the patients
receiving the immunoregulating transfer factor peptides. A protective effect by transfer factor on T-helpers’cell non-specific functional activity was also demonstrated in the results from the inhibition reaction of leukocytes’ migration by PHA-R (phytogemagglutinin). In the test group the levels of the main classes of immunoglobulins experienced less hypoimmunoglobulinemia,
another indicator of the immunoprotective effect of Transfer Factors.
D. Clinical and Immunological Effectiveness of Transfer Factor in the Treatment of Gestation Pyelonephritis.
O.G. Tsoy, V.V. Tian, G.U. Akhmed’anova, Sh.V. Abdugalimov. Kazakh State Medical Academy, Astana
The study group consisted of fifteen (15) pregnant women (gestation period 28 weeks) with gestational pyelonephritis (acute, aggravated chronic) that were treated in the pregnancy pathology department of the 1st City hospital. The immunomodulator Transfer Factor™, a biologically active supplement (BAS) produced by a USA company 4Life, was used in the study. The regiment included 1 capsule of Transfer Factor™ 3 times daily for 10 days in the treatment complex.
The clinical and immunological effectiveness of Transfer Factor was confirmed in both clinical laboratory analyses and specific immunological investigations. There was statistically significant increase of absolute number of total lymphocytes (p<0.001)>
E. Transfer Factor is a Modifier of Biological Age
A.G. Chizhov, V.A. Santalova Russian People’s Friendship University, Moscow
There is a close link between the decrease of functional activity of the immune system and aging. Thus, we decided to study immunomodulators to determine to what extent they may
affect biological age indices. A new immune theory of aging (V.I.Dontsov, V.N. Krut’ko, 2002) points to the role of specific T-lymphocytes subpopulations in sustaining a certain level of normal cellular growth in the body and dwells on the importance of their functional decrease having
a strong impact on aging. Stimulation of the function of these cells by Transfer Factor (TF), an immunomodulator produced by 4Life, USA, seemed a plausible method of “treating aging”. The evaluation of the role TF in the process of aging is at the basis of this study.
Twelve (12) men aged 55-73 were included in the study. A dose of 300 mg. of the TF product was given daily with meals 5 times a week for 6 weeks. Biological age was determined
using the “АPK” method (“Diagnostics of aging: biological age” (National gerontology center, Moscow)). The following biomarkers were used for making the determinations: AP (arterial pressure), pulse wave velocity, VC (vital pulmonary capacity), static balance, Shtange’s test,
adaptation testing, body mass, left hand strength, Shulte’s test, Veksler’s test, neuromuscular test, hearing frequency threshold and the SAN’s questionnaire. The functional activities of body systems were evaluated by means of Nakatani’s electropuncture diagnostics. Chronological age of the group was 63.5±0.7. Before the use of TF the biological age of the group differed from chronological by -4.2 ±0.6 years. The majority of men demonstrated a decrease in the
functional activity of endocrine and of immune systems’ as well as hyperfunction of the liver and of urinary bladder and hypofunction pancreatic.
Results: The study showed that initially disturbed body system functions were significantly normalized. After the course of TF treatment the difference between biological and chronological age was (-8.2) ±0.5 years (p<0.05),>rejuvenation effect of 4 years!
11. HEPATITIS B & C
a) CLINICAL DIAGNOSIS: CHRONIC HEPATITIS C : A.C. , 44 years old, married, female with a history of blood transfusion secondary to massive bleeding when she delivered her third baby in Saudi Arabia. Patient took advantage of health benefits of his son, so she underwent a comprehensive executive check-up.
REMARKABLE FINDINGS:
Physical examinations: hepatomegaly , tenderness on palpation at the right upper quadrant of abdomen;
Diagnostic Tests: Abdominal ultrasound- beginning cirrhotic liver.
Elevated liver enzymes: SGPT, SGOT Hepatitis C- Reactive
CLINICAL DIAGNOSIS: CHRONIC HEPATITIS C
PLAN OF MEDICAL MANAGEMENT:
June 1, 2009: Interferon ∞-2B, 3 MIU (Million international Unit)/vial
Subcutaneous injection for 48 weeks, 1 vial per week
Transfer Factor Tri-Factor, 2 capsule 3x a day
June 30, 2009: After 4 weeks of the said treatment,
Repeat physical exam. Liver size is now normal
Liver enzymes: normal
Hepatitis C : WEAKLY REACTIVE
JULY 1, 2009: IN JUST 4 WEEKS PATIENT HAS FULLY RECOVERED
b) CLINICAL DIAGNOSIS : HEPATITIS B, HIGHLY INFECTIOUS : R.G. 23years old, single, male, newly graduate eager to seek employment, eldest of 4 siblings. However on medical examinations, he was found out that he is HEPATITIS B surface Antigen positive. Hence, he is not recommended to be fit to work
HEPATITIS PROFILE WAS REQUESTED TO CONFIRM THE
INFECTIOUSNESS OF THE VIRUS.
Result: HbsAg- Reactive
Anti-HbsAg- Non Reactive
HBeAg –Reactive- (THIS POSITIVITY SHOWS THAT
HE IS HIGHLY INFECTIOUS)
Anti-HCV- non reactive
SGPT, SGOT- ELEVATED
Physical examination: icteresia both eyes, palpable liver edge
DIAGNOSIS: HEPATITIS B, HIGHLY INFECTIOUS
Plan of Management:
June 8, 2009
Interferon ∞-2B, 5 MIU (Million international Unit)/vial
Subcutaneous injection for 48 weeks 3 vials/ week
Transfer Factor Tri-Factor, 2 capsule 3x a day
June 30, 2009: After 3 weeks of the said treatment,
Repeat physical exam. Liver edge is no longer palpable
Liver enzymes: slightly elevated HbeAG: NON- REACTIVE
IN 3 WEEKS, A HIGHLY CONTAGIOUS HEPATITIS B WAS REVERTED TO
NON-INFECTIOUS STATE WHICH IS UNUSUAL.
AUGUST 8, 2009: IN JUST 8 WEEKS PATIENT HAS FULLY RECOVERED with SEROCONVERSION (REACTIVE ANTI-HBs). THIS IS A BREAKTHROUGH , A FIRST IN THE PHILIPPINES BECAUSE ACCORDING TO THE AMERICAN GUIDELINES, THERE IS NO CURE FOR HEPA-B. (TF IS NOT A DRUG NOR A CURE, BUT WHAT HAPPENED HERE IS THAT THE IMMUNE SYSTEM
WITH THE HELP OF TF WAS ABLE TO BUILD A CELL-MEDIATED IMMMUNITY CMI AGAINST HEPA-B.
12. KIDNEY TESTIMONIES FROM AROUND THE WORLD
KIDNEY My son has had kidney problems since he was born. This has caused him to be constantly weak and constipated. His urine was also very cloudy. He is now 12 years old and needless to say he has suffered for 12 years. Every 3 days he had to be taken to the hospital to see the doctor. Then, I started him on Transfer Factor - 4 capsules of Advanced Formula and 60ml Riovida each day. 3 weeks later, I noticed a significant improvement. He was going to the toilet daily, and his urine had cleared up. He had more energy and could go out to play with his friends after school. He could also sweat when he could not previously. Before Transfer Factor, I had put him on many different types of medication and food supplements which have never helped. Transfer Factor has changed everything and improved his health. I have full confidence that Transfer Factor is very effective.
Chua Lea Ping, 45 years old, Female, Seremban, Negeri Sembilan, Malaysia.
KIDNEY A couple of weeks ago I got very, very ill--so ill that I had to go to the hospital. I had a tremendous pain in my side and I was pretty sure I had a kidney infection. It usually keeps me down for about 20 days. For a week and a half, I couldn't eat and I threw up and had diarrhea all day long. My husband got in contact with someone who was a distributor at the company and I decided to quit all my other pills and just take transfer factors. The next day, I took nine--three in the morning, three in the afternoon, and three at night. The day after that, I had my first meal. I was grateful that I felt so much better. I really believe it's the transfer factors that have given me the energy that I need. Isabel A.
KIDNEY "My mother, who has suffered with a serious kidney disease for the past 10 years, and tore her Achilles tendon away from the bone around a year ago, began taking transfer factors, along with Fibro AMJ, 7 days ago. She has been taking about 10-12 prescriptions for the above conditions, none of which had helped with her heel problems. Starting on the 4th day of taking the T.F. & Fibro AMJ (A.M.), at the recommended dosage of 3 each per day, she began to notice an improvement. Today, she says it's better than it's been for a very long time, and is reporting that she's also feeling an improvement in her general well-being. She must be, since over the past few days she has vacuumed her house, washed some windows, and washed & waxed her car. That's more activity than I've seen from her in years! Many thanks to everyone involved with these remarkable products. My mother-in-law is starting the same regimen next week. I'll keep you posted on her progress, as well." Jill.
KIDNEY-NEPHROTIC My son Jasper, was diagnosed with nephrotic syndrome (in laymen terms - kidneys not able to sieve protein molecules) when he was 11 months old. He is now 7 years old. His prognosis was not good; his health got worse from year to year. I almost lost him on September 11, 2001 after he went into shock and lost consciousness due to attacks form Chicken Pox and another stomach virus. I was advised by the doctors to improve his immune system, otherwise he will have a high chance of having kidneys failure in 2002. He has been treated with steroids, so much that he had become steroid dependent. The toxicity of steroids can be seen on his face and all over his bloated body. In June of 2002 I started him on TF+, 6 a day. I could see visible results after only 2 weeks. His hairy hands and body became not so hairy. He started to slim down. His daily pee test showed no trace of protein. Since then he is sick less and he recovered from a cough without antibiotics. So far, he has not fallen ill except for 2 times of cough virus attacks. This is unlike the past when I had to visit the doctors for antibiotics every other week. Currently, he is living like any other normal kid. I do not need to control his diet. He was on salt free diet for the past 5 years. CY, Malaysia.
KIDNEY INFECTION The grandmother of my friend was in the hospital with a severe kidney infection. The doctors had planned on putting her on kidney dialysis. My friend gave her Chioce 50 and TF+ while in the hospital. Within days the infection cleared up and the doctors sent her home saying that she does not need the kidney dialysis. My family has taken grapeseed for may years and truly believe in its healing power. We are extremely happy with the products and would recommend them to anyone. Darlene, NC.
KIDNEY FAILURE Originally Cynthia was taken to the emergency room in very serious condition and then she was placed in ICU, where she has remained since then. The head physician didn't see how she could live. The bacteria had ravaged her muscles, liver, pancreas, and kidneys. For at least ten days Cynthia has suffered from kidney failure gaining over 30 pounds since she could not eliminate liquid. They used furosemide to move some of the liquid through her, but the kidneys were not purifying. The kidney marker was up to 12+ and the physician didn't believe there was much chance that the kidneys would ever function again. We talked the physician into using transfer factors after it didn't look like the antibiotics were going to do the job and seemed that the kidneys were to far gone. I am very happy to report that we got word from the hospital today 13 days later that Cynthia is be released tomorrow from the hospital. One of the nurses said, "she had never seen a patient come back from the condition that Cynthia was in, it must have been divine intervention." Of course we cannot know exactly what the total answer was that saved Cynthia's life. Cynthia has been ill for 17 years. Before she had this last event, her body weight was down to 89 pounds so when she was hit by this ravaging infection it was considerably more dangerous. The doctors shared no hope that she could recover, actually just the opposite. Today she is laughing, joking and excited about going home. Was it transfer factors? Was it the wonderful care of the doctors and nurses? Was it prayer? Maybe all three. We are finding over and over again that wonderful things can happen when your immune system is filled with intelligence and working at top efficiency. Thanks for all of your prayers. Kay Bergen for Cynthia Bergen
Click to Watch Transfer Factor Testimonial Videos from YouTube
13. FAQs ON TRANSFER FACTOR
"Treating Chronically Ill Patients With Transfer Factor"
A discussion by Dr. Carol Ann Ryser, M.D.
A discussion by Dr. Carol Ann Ryser, M.D.
Dr. Carol Ann Ryser, M.D., is a Board Certified Pediatrician, Board Certified Clinical Analyst, member of F.A.A.P., the American Medical Association, OHM (Orthomolecular Health Medicine), and the American Academy of Anti-Aging Medicine. The primary focus of Dr. Ryser’s medical practice is on the prevention of illness and disease. Since 1996, Dr. Ryser has been the Medical Director of Health Centers of America
Dr. Ryser has published and presented a number of papers in her area of expertise, appearing in such publications as The American Journal for Diseases of Children, the Journal of Neurology, Neurosurgery and Psychology and Pediatrics. Dr. Ryser has been recognized for her contributions in the fields of medicine, science, and mental health, as both a clinician and educator, by both professional and lay organizations.
Overview:
The use of transfer factor represents one of the most exciting advances in immune system health. transfer factor is based on the fact that key immune information can be transferred from cell-to-cell. These cells then teach the immune system to recognize specific viruses and bacteria.
Transfer factors are tiny protein molecules that are produced by immune cells called T-cells. Transfer factors allow the immune system to remember conditions for which immunity has already been established. When a person has been infected, for example, with chicken pox in childhood, their body develops a memory of that illness, and prevents the person from becoming re-infected with it later in life. In the future, the specific immune transfer factor molecule for chicken pox will endow the immune system with the exact ‘blueprint’ of what chicken pox looks like, and the body will be able to quickly recognize and respond to any possible re-infection.
Many of these transfer factors - or “immune memory molecules,” were introduced to us from our mother’s milk or colostrum, which is the richest source of concentrated transfer factors known to scientists. Transfer factors in colostrum have the sole purpose of transferring immunity from the mother to the baby’s immature immune system. All mammals produce transfer factor, but scientists prefer to work with chicken and normal bovine colostrum. A healthy cow already produces millions of different transfer factors, but when the cow comes into contact with a pathogen such as a virus, it produces a new transfer factor for that specific virus or pathogen.
For individuals challenged by specific pathogens – such as those suffering with chronic illnesses like Chronic Fatigue Syndrome, supplementation with the appropriate transfer factor molecule may provide the ‘missing link,’ thereby allowing the immune system to target and destroy the offending pathogen, and mitigate the symptoms of the disease.
Since 1998, Dr. Carol Ann Ryser has been using transfer factor to treat her chronically ill patients, and has experienced considerable success in diminishing symptoms and achieving overall health improvements among those patients. In this exclusive interview, Dr. Ryser discusses her experience with transfer factor as an effective treatment for chronic illness.
Question: What transfer factor do you use in your practice, and for what kind of patient?
Dr. Ryser's Response: For chronically ill patients, including those with chronic sinusitis, and multiple allergies, I prescribe six capsules a day, and depending on the severity of their symptoms, I might prescribe up to twelve capsules a day. For Epstein-Barr patients, I typically prescribe three capsules a day of Transfer Factor Plus for adults, taken morning or evening as they prefer, because it can make them tired. For children ages 7-12 or 13, depending on weight, I will prescribe two capsules a day, to be taken at bedtime.
When a patient is beginning to get sick and is coming down with a fever, I will have them take two capsules every 2-3 hours, for 24 hours, and that usually knocks the virus “off its socks,” so to speak. This dosage of transfer factor can nip a fever in the bud, by supporting the immune system’s natural killer cells.
I have also found that a blend of transfer factor formulas can be very effective. For patients with Herpes Virus 1 or the common cold, I might prescribe six capsules a day of the plain transfer factor, Transfer Factor Advance or the Transfer Factor Plus, to specifically target the virus they are trying to fight.
I also treat fibromyalgia patients with transfer factor. I believe that fibromyalgia is most commonly caused by infections, including bacteria, yeast, and parasites. For chronically ill patients dealing with multiple infections, including CNS (Central Nervous System) infections and gastrointestinal infections, I recommend several different transfer factor formulas, to be taken together.
In treating a chronically ill patient, viruses need to be suppressed. Stress –both physical and emotional, will activate the immune system and “distract” it to deal with the new stressor that has been introduced. That is why so many college students come down with mononucleosis.
If a patient isn’t getting good results with transfer factor, I look at possible coagulation problems, as well as malabsorption difficulties, and gastrointestinal problems. I always begin by getting a patient’s bowels functioning more normally (I address Irritable Bowel Syndrome), so they can properly absorb transfer factor.
Question: How long does it usually take for a patient to experience positive results once they start taking transfer factor?
Dr. Ryser's Response: My patients usually start to feel better within 3-6 months of beginning treatment with transfer factor. Dramatic results usually manifest in about one year, but we really begin to see positive changes in 5-6 months. It typically takes about a year of transfer factor treatment to really turn a patient around. I am specifically referring to chronically ill patients who have an average of 2-7 chronic infections that require treatment. The body’s cells regenerate every six months, and you need to give the body a chance to generate healthy cells before dramatic improvements in a patient’s overall health can emerge.
Question: What, if any, are the side effects or possible negative reactions that can occur with transfer factor therapy?
Dr. Ryser's Response: The initial reactions to transfer factor a patient will experience are similar to a vaccination – but without, of course, exposure to the pathogen. The initial reaction typically includes flu-like symptoms, proportionate to the severity of a patient’s illness. These flu-like symptoms go away, but they prove that the immune system has been activated, and that it is working to suppress the body’s infections.
Regarding the safety of transfer factor, I have never had a problem with negative side effects or adverse reactions. However, I am very cautious. I perform careful evaluations of a patient’s immune system. I check for viral leukemia, and so forth. I am very careful with cancer and autoimmune patients, with whom you must be cautious with regard to stimulating immune cells – this is particularly the case with Hodgkins Disease and Non-Hodgkins Lymphoma patients.
Question: What have you found to be the most positive benefits of transfer factor for your Chronic Fatigue Syndrome patients – what are the best results you have seen?
Dr. Ryser's Response: The patient stops getting sick, and they don’t have any more infections. Their cognitive thinking clears up – no more brain fog. Their energy comes back – they can start doing more, and they can start walking and exercising again. They don’t suffer relapses. However, when a patient is doing well and they make the personal decision to stop taking transfer factor, I have seen relapses. I strongly recommend that a patient takes transfer factor for life – that is, it is a lifetime commitment for my chronically ill patients.
"I have used these products as stand-alone and in conjunction with allopathic therapies in the following cases with excellent results: (Note all cancer cases were given Transfer Factor Tri-Factor Advanced Formula only - also referred to as CANCER: Canine lipomas, Canine/feline hepatic tumors, Equine squamous cell carcinoma, Equine melanomas; Feline leukemia, oral tumors.
VIRAL/BACTERIAL: Upper and lower respiratory infections, Canine/feline dermatoses, Equine/bovine scours, Equine septic arthritis, Feline abscesses. PARASITIC/FUNGAL/AUTOIMMUNE: E.P.M., Feline and equine fungal dermatitis, and Feline autoimmune gingivitis." Steven Slagle, DVM NOTE: A number of veterinarians use the human formula of transfer factors in their practices. Diana Mc Cormick owns a magnificent black purebred Andalusianstallion, Amistad. The horse fully recovered from his cancer and other health problems with 6 capsules of Transfer Factor twice a day. A year later, Diana wrote me: "The Tumor did not reappear or Amistad did not have any set backs since I nursed him through that winter after the surgery and the following Spring. Amistad looks magnificent and he is winning everywhere, producing foals and making many more. At this time Amistad is actually in the process of being sold for $80.000 to a wonderful lady in MI. So miracles do happen, had we gone with the radiation, chances are he would have broken a leg with the weak bones and he would be sterile."
Joe Raemakers, DVM - "We recently had an experience with a 30-year-old horse who had a leg swollen from infection. I applied Transfer Factor directly to the leg and within 6 days the swelling was totally gone. I checked his lymphocyte level and he had a 27% increase since the use of transfer factors. THAT’S JUST PHENOMENAL!"
15. Some Local Write-Ups (PDI Column by Cory Quirino)
16. PROFILES OF CYTOKINE PRODUCTION IN RECIPIENTS OF TRANSFER FACTORS
Linda Alvarez-Thull and Charles H. Kirkpatrick Innovative Therapeutics, Inc. and The Divisions of Allergy and Clinical Immunology National Jewish Center for Immunology and Respiratory Medicine and the University of Colorado Health Sciences Center Denver, Colorado, USA
Transfer factors (TF) are proteins that transfer the ability to express cell-mediated immunity from immune donors to non-immune recipients. The mechanisms of these effects have not been defined. The experiments described in this report were undertaken to test the hypothesis that a mechanism through which the beneficial effects of TF are expressed in clinical situation is through "education" of the immune system to produce certain cytokines in response to antigenic stimulation. BALB/c mice were sensitized to Herpes simplex virus (HSV) either by sublethal systemic or cutaneous infections by administration of a HSV-specific TF. One week later their spleen cells were collected and single cell suspensions were stimulated in vitro with irradiated HSV or concanavalin A. Culture supernatants were collected and assayed for content of IL-2, IL-4, IL-10 and IFN-g.
Spleen cells from infected mice responded to concanavalin A and to HSV by secreting large amounts of IL-2 and IFN-g, modest amounts of IL-10, and no IL-4. Transfer factor recipients produced similar cytokine profiles in response to concanavalin A. These mice, however, responded to HSV by secreting IFN-g, but no IL-2. Thus, TF treatment selectively affects cytokine production in response to antigenic stimulation.
Ref. http://www.biotransfer.org/art03.html
MdProLife Primary Vision:
To Eradicate Lifestyle Diseases &
Infectious Diseases in the Philippines MdProLife Secondary Vision:
To Extend Quality Life MdProLife Mission Statement:
To Organize Health Awareness Campaign through Tri-Media
To Eradicate Lifestyle Diseases &
Infectious Diseases in the Philippines MdProLife Secondary Vision:
To Extend Quality Life MdProLife Mission Statement:
To Organize Health Awareness Campaign through Tri-Media
P.S. Book Launching will be announced soon!
CLICK TRANSFER FACTOR TO BUY PRODUCTS AS CUSTOMERS ON-LINE:
(IMPORTANT NOTE: ASK YOUR FRIEND OR THE DISTRIBUTOR WHO INVITED YOU TO GO TO THIS SITE FOR DETAILS)
(IMPORTANT NOTE: ASK YOUR FRIEND OR THE DISTRIBUTOR WHO INVITED YOU TO GO TO THIS SITE FOR DETAILS)
Email me, Mon Mendoza at mdprolife@gmail.com
or you can also text me at +63 9222453738 (Suncel) or call me at +632 4251202 (Direct Line).
Author's Note: By the way, for your information, there are now 2,500 New Cases of Leprosy in the Philippines yearly. You and I can do something to stop this.
Author's Note: By the way, for your information, there are now 2,500 New Cases of Leprosy in the Philippines yearly. You and I can do something to stop this.
FOR INQUIRIES AND FREE SEMINAR BOOKINGS, YOU MAY CALL THE AUTHOR AS FOLLOWS:
HOTLINE NUMBERS:
Suncel: (63) 9235742092
Hotline: (632) 7740890
DESCLAIMER:
TRANSFER FACTOR IS NOT A DRUG
TRANSFER FACTOR IS NOT A CURE
TRANSFER FACTOR FOCUSES ON THE IMMUNE SYSTEM TO EDUCATE, ENHANCE AND BALANCE THE IMMUNE SYSTEM
TRANSFER FACTOR FOCUSES ON THE T-LYMPHOCYTES (KILLER T-CELLS) TO INDUCE A CELL-MEDIATED IMMUNE RESPONSE
Visit https://4lifephilippines.com/what-is-transfer-factor/
ReplyDelete